Post-Exposure Prophylaxis Initiated Beyond the Recommended 72-Hour Window

Critical Timing Considerations

The Centers for Disease Control and Prevention recommends that Post-Exposure Prophylaxis (PEP) be initiated within 72 hours of exposure for optimal effectiveness, with guidelines strongly recommending initiation within this timeframe 1, 2, 3
Animal studies suggest that PEP is probably not effective when started later than 24-36 hours post-exposure, though the exact interval beyond which there is no benefit in humans remains undefined 4, 5
For exposures beyond 72 hours, guidelines acknowledge that while efficacy is diminished, there is no absolute cutoff beyond which PEP provides zero benefit 1
The risk-benefit calculation shifts when using safer, more tolerable modern regimens, such as dolutegravir-based therapy, versus older toxic regimens, making late initiation more justifiable for high-risk exposures 1

The American College of Physicians and the Centers for Disease Control and Prevention recommend dolutegravir plus tenofovir disoproxil fumarate/emtricitabine as a preferred regimen for PEP 2, 3
This regimen should be continued for the full 28-day course 2, 3

The patient should continue the current regimen to complete 28 days total from initiation, as recommended by the Centers for Disease Control and Prevention 2, 3
Baseline renal and hepatic function should be assessed, as recommended by the Morbidity and Mortality Weekly Report 5
The exposure risk level should be evaluated, including the type of exposure, known HIV status of the source, and viral load if known, as recommended by the Centers for Disease Control and Prevention 1
For highest-risk exposures, even delayed PEP may offer benefit, as early treatment of acute infection can be beneficial even if transmission is not prevented 4, 5

The Centers for Disease Control and Prevention recommends that PEP not be discontinued prematurely based solely on the delayed start, as the medication is already initiated and well-tolerated 1
The patient should be counseled that while efficacy is reduced with delayed initiation, completing the course is still worthwhile and safer modern regimens justify continuation, as recommended by the Centers for Disease Control and Prevention 1
The patient should receive risk reduction counseling and support throughout the PEP course to maximize adherence, as recommended by the Centers for Disease Control and Prevention 1

The Centers for Disease Control and Prevention (CDC) recommends a 28-day PEP regimen that includes Descovy (emtricitabine 200 mg/tenofovir alafenamide 25 mg) taken once daily as part of a complete regimen that should also include an integrase strand transfer inhibitor 6, 7
The CDC recommends the preferred regimens for adults and adolescents requiring PEP, including either Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as a single tablet regimen or Dolutegravir plus emtricitabine/tenofovir alafenamide (Descovy) 6, 7, 8

The CDC recommends Descovy (emtricitabine/tenofovir alafenamide) dosage for PEP as one tablet (200 mg/25 mg) taken orally once daily 8, 9
The CDC states that when using Descovy as part of a PEP regimen, it should be taken with or without food 10

The CDC recommends performing HIV testing (rapid or laboratory-based antigen/antibody combination test) before initiating PEP 6, 7
The CDC recommends follow-up HIV testing at 4-6 weeks after exposure and 12 weeks after exposure (final HIV test) 6, 7

The CDC recommends stopping PEP if at any point during the course the source is found to not have HIV 6, 7
The CDC suggests considering transition from PEP to PrEP after completion of the 28-day PEP course for individuals with anticipated ongoing HIV exposure risk 6, 7

PEP should be initiated as soon as possible, preferably within 1-2 hours after exposure, but can be started up to 72 hours post-exposure, according to the CDC guidelines 11
Laboratory monitoring should include baseline and follow-up renal and hepatic function tests, as recommended by the CDC 12
For occupational exposures, additional testing for hepatitis B and C should be considered, as suggested by the CDC 11

The World Health Organization recommends tenofovir-based regimens for PEP, supporting the use of Descovy 13

Earlier PEP regimens used older antiretrovirals like zidovudine (AZT), lamivudine (3TC), and protease inhibitors, as reported by the CDC 14, 15, and 16